DGX vs NEOG

For growth investors, Quest Diagnostics Incorporated (DGX) is the stronger pick with 11.

8% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). Quest Diagnostics Incorporated (DGX) offers the better valuation at 21. 8x trailing P/E (17. 8x forward), making it the more compelling value choice. Analysts rate Quest Diagnostics Incorporated (DGX) a "Hold" — based on 34 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Quest Diagnostics Incorporated is actually cheaper at 17.

8x.

Over the past 5 years, Quest Diagnostics Incorporated (DGX) delivered a total return of +47.

7%, compared to -80. 6% for Neogen Corporation (NEOG). Over 10 years, the gap is even starker: DGX returned +181. 3% versus NEOG's -49. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Quest Diagnostics Incorporated (DGX) is the lower-risk stock at 0.

07β versus Neogen Corporation's 1. 83β — meaning NEOG is approximately 2391% more volatile than DGX relative to the S&P 500. On balance sheet safety, Neogen Corporation (NEOG) carries a lower debt/equity ratio of 44% versus 95% for Quest Diagnostics Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Quest Diagnostics Incorporated (DGX) is pulling ahead at 11.

8% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: Quest Diagnostics Incorporated grew EPS 13. 8% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, NEOG leads at 19. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Quest Diagnostics Incorporated (DGX) is the more profitable company, earning 9.

0% net margin versus -122. 1% for Neogen Corporation — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DGX leads at 14. 5% versus 1. 1% for NEOG. At the gross margin level — before operating expenses — NEOG leads at 47. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Quest Diagnostics Incorporated (DGX) trades at 17.

8x forward P/E versus 25. 9x for Neogen Corporation — 8. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NEOG: 18. 9% to $11. 00.

In this comparison, DGX (1.

6% yield) pays a dividend. NEOG does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Quest Diagnostics Incorporated (DGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

07), 1. 6% yield, +181. 3% 10Y return). Neogen Corporation (NEOG) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DGX: +181. 3%, NEOG: -49. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

DGX pays a dividend while NEOG does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.